<DOC>
	<DOCNO>NCT01037881</DOCNO>
	<brief_summary>This proof concept dose find Phase II trial compare 5 dose strength vehicle active comparator ( Elidel cream 10 mg/g ) 4 week , twice daily treatment regimen mild moderate atopic dermatitis patient .</brief_summary>
	<brief_title>LEO 29102 Cream Treatment Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<criteria>Clinical diagnosis atopic dermatitis define accord Hanifin Rajka IGA assessment score mild ( 2 ) moderate ( 3 ) atopic dermatitis Treatment lesion locate trunk limbs Treatment lesion involve 3 % 10 % total body surface area Patients either gender 18 year 65 year age Systemic treatment immunosuppressive drug corticosteroid within 6 week prior randomisation Topical treatment immunomodulators ( pimecrolimus , tacrolimus ) within 2 week prior randomisation Topical treatment corticosteroid WHO group II , III IV within 1 week prior randomisation Use topical systemic antibiotic within 2 week prior randomisation PUVA UVB therapy within 4 week prior randomisation Clinical infection ( viral , fungal bacterial ) treatment area Known suspect severe renal insufficiency severe hepatic disorder Patients history immunocompromised disease ( e.g. , lymphoma , HIV , WiskottAldrich Syndrome ) Patients concomitant serious disease ( e.g. , cancer ) might affect AD treatment trial Females pregnant breast feeding Females intend temporarily permanently stop hormonal contraceptive regime one month post study termination visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>